Healthcare Q&A: Chris Garabedian on Sarepta’s Plans for Eteplirsen

Chris Garabedian, President and Chief Executive Officer of Sarepta, told Bloomberg Brief: Healthcare Finance’s Elizabeth Krutoholow that the results seen with lead drug eteplirsen for Duchenne Muscular Dystrophy (DMD) have provided proof-of-concept to support the company’s phosphorodiamidate morpholino oligomer technology. He said the company will focus on DMD and eventually other rare genetic diseases. Sarepta will be requesting a meeting with the FDA to discuss the design of confirmatory studies as well as the feasibility of using the current data set to file for accelerated approval.

To read the full Q&A click here

Bloomberg BRIEF Newsletters